Current Edition

clinical trial

Targovax announces that TG02 has passed the initial safety review in the first-in-man clinical trial in colorectal cancer

Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces that TG02 has passed the initial …

Continue Reading →
antibody

Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinoma

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive topline results from a pivotal Phase 2 clinical study of cemiplimab in 82 patients with …

Continue Reading →
immuno-oncology

Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews

Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that clinical trials investigating ONCOS-102 in the …

Continue Reading →